QT Imaging Reports Record 2025 Revenue, Exceeds Guidance, Projects $39M Revenue for 2026
QTI has more than doubled off its 52-week low of $0.321 on light trading volume (0.3× avg).
Summary
QT Imaging Holdings announced record Q4 and full-year 2025 financial results, exceeding revenue guidance, and provided a strong 2026 revenue outlook of $39 million, signaling significant growth.
Key Events · Earnings and Guidance · QTI
-
Record 2025 Financial Performance
Reported record Q4 2025 revenue of $8.3 million, up 97% sequentially and 877% year-over-year. Full-year 2025 revenue reached $18.9 million, exceeding guidance of $18.0 million and representing 288% growth over 2024. Net loss improved by 60% in Q4 2025, and Adjusted EBITDA improved by 52% for the full year.
-
Strong 2026 Revenue Outlook
Projected 2026 revenue of approximately $39 million, including scanner shipments and initial revenue from its SaaS Cloud Platform, indicating a significant acceleration in growth.
-
Strategic Partnerships and Distribution Expansion
Entered collaborations with Intelerad Medical Systems and Olea Medical to enhance its QTI Cloud SaaS Platform. Secured an exclusive distribution agreement in the UAE with Al Naghi Medical Co., committing to minimum orders of 43 scanners for over $24 million in revenue from 2026-2028.
-
Strengthened Financial Position and Market Presence
Successfully completed a private placement raising $18.2 million in gross proceeds and uplisted to the Nasdaq Capital Market, enhancing financial stability and market visibility.
Analysis · QTI · Industrial Applications And Services
QT Imaging Holdings delivered exceptionally strong financial results for 2025, surpassing its revenue guidance and demonstrating significant operational momentum. The company achieved record revenue in Q4 2025 and for the full year, driven by increased scanner shipments and strategic partnerships. The substantial 2026 revenue outlook of $39 million, more than double the 2025 figure, signals a robust growth trajectory and successful execution of its pivot towards a SaaS and biomarker-driven medical imaging platform. While the company reported a net loss, the improvement in Adjusted EBITDA and the focus on non-cash expenses indicate a healthier operational trend. The strategic collaborations and distribution agreements, particularly the multi-year UAE deal, underpin the ambitious future guidance and enhance the company's market reach and revenue visibility.
At the time of this filing, QTI was trading at $5.68 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $67.5M. The 52-week trading range was $0.32 to $8.50. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.